Evalve Expands Executive Leadership Team(d eager to take on theresponsibility of ...),Health

Date:10/9/2008

d eager to take on the responsibility of leading the expansion and growth of Evalve as we begin sales in Europe and gear up for U.S. commercialization," said Cleary. "I look forward to working with Chris and the Evalve team to establish the MitraClip system as a non-surgical treatment of choice for patients suffering from mitral regurgitation."

As vice president of sales, Chris Richardson will report to Cleary and will be responsible for developing the European market for Evalve's first in class therapy in conjunction with preparing for U.S. commercialization. Richardson will focus on driving adoption of the MitraClip system through implementation of education and training programs for physicians. Like Cleary, Richardson joins Evalve from Boston Scientific where he championed regional sales and directed management development for Guidant Corporation (prior to its acquisition by Boston Scientific). Chris most recently was vice president of cardiac rhythm management sales for the southeast area, driving significant market growth and increases in profitability for the company.

About the MitraClip Procedure

Percutaneous mitral repair with Evalve's MitraClip device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart-lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.

About Evalve, Inc.

Founded in 1999, Evalve, Inc. -- headquartered in Menlo Park, California -- has developed a proprietary system which enables percutaneous repair of cardiac valves. The
'/>"/>

SOURCE Evalve, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Evalve Announces Enrollment Completion of the EVEREST Randomized Study
2. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
3. Particle Sciences Expands Its Combination Product Capabilities
4. Spherix Expands Phase 3 Naturlose Diabetes Trial Outside of the U.S.
5. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
6. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
7. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
8. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
9. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
10. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
11. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program